Current Report Filing (8-k)
January 09 2017 - 8:31AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of report (Date of earliest event reported):
January 9, 2017
ADVAXIS,
INC.
(Exact
Name of Registrant as Specified in Charter)
Delaware
|
|
000-28489
|
|
02-0563870
|
(State
or Other Jurisdiction
|
|
(Commission
|
|
(IRS
Employer
|
of
Incorporation)
|
|
File
Number)
|
|
Identification
No.)
|
305
College Road East
Princeton,
New Jersey, 08540
(Address
of Principal Executive Offices)
(609)
452-9813
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act.
|
|
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act.
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2b under the Exchange Act.
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act.
|
Item
7.01 Regulation FD Disclosure.
A
copy of the press release of Advaxis, Inc. (the “Company”) dated January 9, 2017 relating to the announcement discussed
in Item 8.01 below is attached hereto as Exhibit 99.1.
The
information furnished pursuant to this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities
under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities
Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item
8.01 Other Events.
On
January 9, 2017, the Company announced its business outlook for 2017, including clinical development and expanding pipeline milestones.
Item
9.01. Financial Statements and Exhibits.
The following
exhibit is furnished as a part of this report
|
99.1
|
Press
Release dated January 9, 2017.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
ADVAXIS,
INC.
|
|
(Registrant)
|
|
|
|
|
By
|
/s/
Daniel J. O’Connor
|
|
|
Daniel
J. O’Connor
|
|
|
President
and Chief Executive Officer
|
Date:
January 9, 2017
INDEX
TO EXHIBITS
Exhibit
|
|
|
Number
|
|
Description
|
|
|
|
99.1
|
|
Press
Release dated January 9, 2017.
|
Ayala Pharmaceuticals (QX) (USOTC:ADXS)
Historical Stock Chart
From Apr 2024 to May 2024
Ayala Pharmaceuticals (QX) (USOTC:ADXS)
Historical Stock Chart
From May 2023 to May 2024